Artículos por temáticas
En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.
FILTRAR POR:
Por tema
Tratamiento no farmacológico
358 ARTíCULOS , VIENDO DEL 166 AL 180
Do tocotrienols have potential as neuroprotective dietary factors?
Frank J, Chin XW, Schrader C, Eckert GP, Rimbach G.
Ageing Res Rev. 2012 Jan;11(1):163-80. doi: 10.1016/j.arr.2011.06.006. Epub 2011 Jul 7.
0
0
0
Alzheimer's therapeutics: translation of preclinical science to clinical drug development
Savonenko AV, Melnikova T, Hiatt A, Li T, Worley PF, Troncoso JC, Wong PC, Price DL.
Neuropsychopharmacology. 2012 Jan;37(1):261-77. doi: 10.1038/npp.2011.211. Epub 2011 Sep 21.
0
0
0
Manipulation of microglial activity as a therapy for Alzheimer's disease
Tan B, Choi RH, Chin TJ, Kaur C, Ling EA.
Front Biosci (Schol Ed). 2012 Jun 1;4(4):1402-12. doi: 10.2741/s342.
0
0
0
Hooijmans CR, Pasker-de Jong PC, de Vries RB, Ritskes-Hoitinga M.
J Alzheimers Dis. 2012;28(1):191-209. doi: 10.3233/JAD-2011-111217.
0
0
0
Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P; Alzheimer’s Disease Cooperative Study.
Arch Neurol. 2012 Jul;69(7):836-41. doi: 10.1001/archneurol.2012.85.
0
0
0
A review of the major vascular risk factors related to Alzheimer's disease
Polidori MC, Pientka L, Mecocci P.
J Alzheimers Dis. 2012;32(3):521-30. doi: 10.3233/JAD-2012-120871.
0
0
0
Alzheimer's disease 2012: the great amyloid gamble
Marchesi VT.
Am J Pathol. 2012 May;180(5):1762-7. doi: 10.1016/j.ajpath.2012.03.004. Epub 2012 Apr 1.
0
0
0
New and emerging treatments for Alzheimer's disease
Corbett A, Smith J, Ballard C.
Expert Rev Neurother. 2012 May;12(5):535-43. doi: 10.1586/ern.12.43.
0
0
0
Could antivirals be used to treat Alzheimer's disease?
Itzhaki RF, Wozniak MA.
Future Microbiol. 2012 Mar;7(3):307-9. doi: 10.2217/fmb.12.10.
0
0
0
A novel subject synchronization clinical trial design for Alzheimer's disease
Schultz T, Yang E, Farnum M, Lobanov V, Verbeeck R, Raghavan N, Samtani MN, Novak G, Shi Y, Narayan V, DiBernardo A.
J Alzheimers Dis. 2012;31(3):507-16. doi: 10.3233/JAD-2012-120286.
0
0
0
Does lithium prevent Alzheimer's disease?
Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF.
Drugs Aging. 2012 May 1;29(5):335-42. doi: 10.2165/11599180-000000000-00000.
0
0
0
Increasing the success rate for Alzheimer's disease drug discovery and development
Becker RE, Greig NH.
Expert Opin Drug Discov. 2012 Apr;7(4):367-70. doi: 10.1517/17460441.2012.672409. Epub 2012 Mar 23.
0
0
0
Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease
Haas C.
J Alzheimers Dis. 2012;28(2):241-81. doi: 10.3233/JAD-2011-110986.
0
0
0
[Physical exercise in patients with dementia]
Zieschang T, Hauer K, Schwenk M.
Dtsch Med Wochenschr. 2012 Aug;137(31-32):1552-5. doi: 10.1055/s-0032-1305114. Epub 2012 Aug 7.
0
0
0
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A.
Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
